Vyleesi and Acetaminophen Interaction: What Women Need to Know

The Short Answer: Can You Take Vyleesi With Acetaminophen?

You can take bremelanotide and acetaminophen on the same day, but the combination is not as straightforward as it sounds. Bremelanotide slows gastric emptying, which means any oral medication you take around the same time, including acetaminophen, will be absorbed more slowly than expected. The FDA prescribing information for bremelanotide flags this explicitly, noting that co-administration with oral medications can impair their absorption. This is a pharmacokinetic interaction, not a pharmacodynamic one, meaning the drugs are not competing for the same receptor or enzyme pathway. The practical consequence is delayed onset and potentially reduced peak concentration of acetaminophen.

For a woman who takes acetaminophen routinely for menstrual cramps, a headache, or chronic pain, this delay matters. The drug will still work, but not on the timeline your body expects.

How Bremelanotide Changes Drug Absorption in Your Body

Mechanism: Melanocortin Receptors and the Gut

Bremelanotide is a melanocortin receptor agonist. It binds primarily to MC3R and MC4R, receptors distributed throughout the central nervous system and peripheral tissues, including the gastrointestinal tract. Studies in melanocortin receptor pharmacology show that MC4R activation in the gut reduces gastric motility and slows the rate at which stomach contents empty into the small intestine. That process, gastric emptying, is the rate-limiting step for how quickly most orally administered drugs reach systemic circulation.

When gastric emptying slows, the time-to-peak plasma concentration (Tmax) of oral drugs increases. The peak concentration itself (Cmax) may also decrease. For acetaminophen specifically, the FDA label reports a delay in Tmax of approximately one hour and a reduction in Cmax of roughly 15% when co-administered with bremelanotide. The clinical pharmacology section of the bremelanotide NDA review documents this finding from the dedicated drug interaction study conducted during the approval process.

Why Acetaminophen Is the Textbook Example

Acetaminophen is frequently used as a probe drug in gastric emptying studies precisely because its absorption is almost entirely dependent on the rate of gastric emptying rather than on active transport or enzymatic metabolism in the gut wall. Pharmacokinetic research using acetaminophen as a gastric emptying marker has supported this methodology for decades. That makes acetaminophen a sensitive and predictable indicator of any drug that affects gut motility, and it is why the bremelanotide prescribing information specifically calls it out by name.

The interaction is not about CYP enzymes. Acetaminophen is metabolized primarily by UGT1A1, UGT1A6, and UGT1A9, with a minor CYP2E1 and CYP3A4 pathway generating the hepatotoxic metabolite NAPQI. Bremelanotide does not meaningfully inhibit or induce any of these enzymes at therapeutic doses. The absorption delay, not metabolic competition, is the entire story.

Does the Delay Affect Acetaminophen's Safety Profile?

The delay does not increase acetaminophen toxicity risk in most women taking it at normal doses (325 mg to 1,000 mg per dose, no more than 4,000 mg per day in healthy adults). The FDA acetaminophen hepatotoxicity guidance focuses on cumulative daily dose and alcohol co-ingestion as the primary drivers of liver injury risk, not absorption rate variability. A delayed Tmax does not raise your NAPQI burden.

Where this could theoretically matter is if you are using acetaminophen for breakthrough pain and expecting rapid relief. A woman timing acetaminophen for a headache thirty minutes before a social event who also uses Vyleesi that day may find the drug takes nearly twice as long to work.

Timing Guidance: A Practical Framework

The following framework is based on bremelanotide's known pharmacokinetic profile and the acetaminophen absorption data from the FDA clinical pharmacology review. No published randomized trial has tested specific timing windows for managing this interaction, so these recommendations represent a clinically reasonable extrapolation.

Option 1: Take acetaminophen first. Acetaminophen reaches peak plasma concentration within 30 to 60 minutes in a fasted or lightly fed state. If you administer bremelanotide after acetaminophen has already been absorbed, the gastric emptying effect is irrelevant. A gap of at least 60 minutes between oral acetaminophen and your Vyleesi injection is a reasonable buffer.

Option 2: Delay acetaminophen until bremelanotide clears the acute gastric phase. Bremelanotide's half-life is approximately 2.7 hours. Its effect on gastric motility diminishes as plasma concentrations fall. Waiting two to three hours after your injection before taking oral acetaminophen should reduce, though not fully eliminate, the interaction.

Option 3: Switch to a non-oral analgesic on dosing days. Topical diclofenac, a topical NSAID, bypasses gastric absorption entirely. This is not appropriate for every pain type, but it is worth discussing with your prescriber if you regularly use acetaminophen on the same days you use Vyleesi.

Option 4: Skip Vyleesi on days when rapid analgesia is essential. Vyleesi is a per-event, as-needed medication. You are not required to use it on any specific day. If you are managing moderate-to-severe pain and timing of acetaminophen onset matters clinically, that is a legitimate reason to choose a different day for Vyleesi.

Other Bremelanotide Drug Interactions You Should Know

Bremelanotide's gastric emptying effect applies to all oral medications, not just acetaminophen. The prescribing information advises caution with any oral drug whose effectiveness depends on achieving a threshold plasma concentration quickly.

Oral Medications With Time-Sensitive Absorption

The following categories deserve particular attention:

• Oral contraceptives. Many women using Vyleesi are of reproductive age and rely on combined oral contraceptives. If your pill is taken within 60 minutes of a Vyleesi injection, its absorption may be delayed. This does not necessarily reduce contraceptive efficacy given the steady-state pharmacokinetics of most modern pills, but your prescriber should know your OC timing relative to Vyleesi use.
• Antibiotics with narrow therapeutic windows. Drugs like nitrofurantoin or certain macrolides depend on adequate gut absorption. Take them well outside the bremelanotide dosing window.
• Sublingual or buccal formulations. These bypass gastric emptying entirely and are unaffected.

Nausea as a Compounding Factor

Phase III RECONNECT trial data found that nausea occurred in approximately 40% of women using bremelanotide, and vomiting in about 4.5%. If a woman vomits within 30 minutes of taking acetaminophen, she has effectively lost that dose. This is clinically separate from the pharmacokinetic absorption delay, but it compounds the problem practically. Pre-treatment with the antiemetic ondansetron 30 minutes before Vyleesi, a strategy described in the prescribing information, can reduce nausea severity.

Ondansetron itself is not known to significantly affect acetaminophen pharmacokinetics, so this antiemetic strategy does not add further complexity to the interaction.

Who Uses Vyleesi, and Why This Interaction Matters for Different Life Stages

Bremelanotide is FDA-approved exclusively for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The RECONNECT trials enrolled women aged 22 to 55, and the label restricts the indication to premenopausal status. Postmenopausal women were excluded from trials, meaning there is no regulatory basis for using Vyleesi after menopause.

Reproductive-Age Women With HSDD and Chronic Pain Conditions

Women in their reproductive years are disproportionately affected by pain conditions that require regular analgesics. Research published in JAMA indicates that women report higher rates of chronic pain than men across most categories. Endometriosis affects an estimated 1 in 10 women of reproductive age and is frequently treated with NSAIDs or acetaminophen. A woman managing endometriosis-related pain while also treating HSDD with Vyleesi is a realistic clinical scenario where the acetaminophen timing issue becomes genuinely relevant.

Similarly, menstrual migraine, which peaks in the late reproductive years and perimenopause, is often treated with acetaminophen-containing combination analgesics. The bremelanotide interaction does not change the safety of these drugs, but it does affect how quickly they work.

Women With PCOS

PCOS is associated with both sexual dysfunction and chronic inflammatory pain. Women with PCOS are not excluded from the bremelanotide label, though the trials did not analyze this subgroup separately. If you have PCOS and use acetaminophen regularly for joint pain or headaches, the same timing framework applies.

Perimenopause: A Note on Off-Label Use

The FDA label does not include perimenopausal women, whose hormonal status fluctuates between premenopausal and postmenopausal. No clinical trial data support bremelanotide use in this transitional stage. Prescribers sometimes use it off-label in this population, but women in perimenopause should understand the evidence base for their specific hormonal context is thin. The acetaminophen interaction mechanism would be identical, as it is driven by melanocortin receptor pharmacology rather than hormonal status.

Pregnancy, Lactation, and Contraception: A Required Safety Section

Bremelanotide is contraindicated in pregnancy. This is a hard stop. Animal reproduction studies showed fetal harm at doses below the recommended human dose. There are no adequate well-controlled studies in pregnant women. If there is any possibility you are pregnant before using Vyleesi, perform a pregnancy test first.

The FDA prescribing information assigns bremelanotide to the category of drugs with evidence of fetal risk in animal studies and no adequate human data. Women who could become pregnant must use effective contraception throughout bremelanotide use.

Contraception Considerations

Because bremelanotide is used as-needed rather than daily, the contraception interaction question is straightforward: maintain your usual contraceptive method regardless of Vyleesi use. If you rely on oral contraceptives and are concerned about absorption timing on Vyleesi dosing days, discuss barrier backup with your prescriber.

Vyleesi does not have known pharmacodynamic interactions with hormonal contraceptives. The only concern is the same pharmacokinetic absorption delay described above.

Lactation

There is no published human data on bremelanotide transfer into breast milk. The prescribing information notes that animal data suggest excretion into milk is possible. Given the absence of human lactation data and the potential for nausea in the infant, the label recommends women avoid breastfeeding on the day of bremelanotide use. Expressed milk from dosing days should be discarded.

Acetaminophen in breast milk is well-studied and considered compatible with breastfeeding by the American Academy of Pediatrics. The interaction between these two drugs does not change acetaminophen's lactation safety profile.

The Evidence Gap: What We Don't Know

Women have historically been underrepresented in pharmacokinetic drug-drug interaction studies. The bremelanotide-acetaminophen interaction data comes from a single dedicated interaction study conducted during the NDA process, which is standard FDA practice. The study design, subject demographics, and exact protocol are detailed in the clinical pharmacology review, but the trial was not powered to examine whether cycle phase, hormonal contraceptive use, or body composition altered the magnitude of the interaction.

Body weight and fat distribution affect both bremelanotide pharmacokinetics and gastric motility. Pharmacokinetic modeling in the NDA found some weight-related variability in bremelanotide exposure, but this was not directly linked to acetaminophen absorption outcomes. Women with higher body weight may have modestly different bremelanotide Cmax values, but whether that translates to a clinically meaningful difference in the acetaminophen delay is unknown.

Directly studied: the absorption delay in the FDA interaction study cohort. Extrapolated: the one-hour pre-dose buffer recommendation, the timing framework above, and the applicability to women at different cycle phases or BMI ranges.

Who This Is Right For, and Who Should Think Carefully

Good candidates for Vyleesi use with occasional acetaminophen:

• Premenopausal women with acquired, generalized HSDD who occasionally need acetaminophen for mild pain and can plan timing around their injection
• Women who take acetaminophen for menstrual cramps earlier in the day and plan Vyleesi use in the evening
• Women whose analgesic need is not time-critical (e.g., mild general soreness rather than acute migraine)

Women who should talk to their prescriber before combining these:

• Women with chronic pain conditions requiring consistent, rapid acetaminophen onset
• Women managing menstrual migraine where timing of analgesic effect is critical
• Women with liver disease who take acetaminophen near the upper daily dose limit, where any unpredictability in absorption adds complexity
• Women using multiple oral medications that could all be affected by bremelanotide's GI motility effect on the same day

Who should not use Vyleesi at all:

• Women who are pregnant or may be pregnant
• Women who are breastfeeding (on dosing days)
• Women with known hypersensitivity to bremelanotide
• Women with uncontrolled hypertension (bremelanotide transiently raises blood pressure by a mean of approximately 2 mmHg systolic but can cause larger increases in susceptible individuals)

Key Numbers at a Glance

To help you discuss this with your clinician, here are the core pharmacokinetic data points from the FDA record:

• Bremelanotide dose: 1.75 mg subcutaneous, as needed, 45 minutes before anticipated sexual activity
• Maximum frequency: once per 24 hours
• Bremelanotide half-life: approximately 2.7 hours
• Acetaminophen Tmax delay with co-administration: approximately 60 minutes
• Acetaminophen Cmax reduction with co-administration: approximately 15%
• Nausea incidence in RECONNECT trials: approximately 40%
• FDA approval year: 2019 (first non-hormonal, non-CNS-specific treatment for HSDD)

The RECONNECT trial program showed that bremelanotide produced a statistically significant increase in satisfying sexual events versus placebo and a reduction in distress related to low desire. The drug works. Understanding how it affects other medications you take is part of using it well.

Your prescriber should have a full list of every oral medication you take before you start Vyleesi, including over-the-counter drugs like acetaminophen.